Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

BACKGROUND: Safety of rechallenge of immune checkpoint inhibitor (ICI) after grade ≥2 immune-related adverse events (irAEs) leading to ICI discontinuation remains unclear. METHODS: All adverse drug reactions involving at least one ICI reported up to December 31, 2019 were extracted from the French p...

Descripción completa

Detalles Bibliográficos
Autores principales: Allouchery, Marion, Lombard, Thomas, Martin, Mickael, Rouby, Franck, Sassier, Marion, Bertin, Celia, Atzenhoffer, Marina, Miremont-Salame, Ghada, Perault-Pochat, Marie-Christine, Puyade, Mathieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768965/
https://www.ncbi.nlm.nih.gov/pubmed/33428586
http://dx.doi.org/10.1136/jitc-2020-001622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768965/
https://www.ncbi.nlm.nih.gov/pubmed/33428586
http://dx.doi.org/10.1136/jitc-2020-001622

Ejemplares similares